Avadel Pharmaceuticals plc(AVDL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.01 | Insider Own | 5.27% | Shs Outstand | 97.2M | Perf Week | - |
| Market Cap | 2.12B | Forward P/E | 26.39 | EPS next Y | 530.77% | Insider Trans | -68.31% | Shs Float | 92.7M | Perf Month | 0.37% |
| Enterprise Value | 2.06B | PEG | - | EPS next Q | 0.03 | Inst Own | 75.91% | Short Float | 2.49% | Perf Quarter | -5.58% |
| Income | -0.00B | P/S | 8.52 | EPS this Y | 125.49% | Inst Trans | -1.91% | Short Ratio | 0.94 | Perf Half Y | 45.72% |
| Sales | 0.25B | P/B | 21.42 | EPS next 5Y | - | ROA | -0.16% | Short Interest | 2.31M | Perf YTD | 0.42% |
| Book/sh | 1.01 | P/C | 23.11 | EPS past 3/5Y | 27.03% 10.39% | ROE | -0.32% | 52W High | -8.19% ($23.57) | Perf Year | 140.44% |
| Cash/sh | 0.94 | P/FCF | 57.52 | Sales past 3/5Y | - 23.35% | ROIC | -0.21% | 52W Low | 239.18% ($6.38) | Perf 3Y | 178.87% |
| Dividend Est. | - | EV/EBITDA | 251.54 | EPS Y/Y TTM | 99.6% | Gross Margin | 94.47% | Volatility(W/M) | 0.48% 0.33% | Perf 5Y | 138.06% |
| Dividend TTM | - | EV/Sales | 8.3 | Sales Y/Y TTM | 79.88% | Oper. Margin | 1.82% | ATR (14) | 0.09 | Perf 10Y | 134.96% |
| Dividend Ex-Date | - | Quick Ratio | 2.37 | EPS Q/Q | 100.73% | Profit Margin | -0.11% | RSI (14) | 61.58 | Recom | 3.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.76 | Sales Q/Q | 54.86% | SMA20 | 0.38% ($21.56) | Beta | 1.31 | Target Price | $21 |
| Payout | - | Debt/Eq | 0.38 | Earnings | 2025/11/4 | SMA50 | 0.67% ($21.5) | Rel Volume | 0 | Prev Close | $21.64 |
| Employees | 188 | LT Debt/Eq | 0.37 | EPS/Sales Surpr. | -100% 5.29% | SMA200 | 40.29% ($15.43) | Avg Volume(3M) | 2.45M | Price | $21.64 |
| IPO | 1996/6/7 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
💊 Specialty pharmaceutical company focused on sleep disorder treatment. LUMRYZ sales are growing rapidly. Q3 2025 revenue of $7.5M, with 3,400 patients. Alkermes acquisition in progress (Q1 2026).
Over the past 1 year, on the higher side
8% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
AVDL keeps an operating profit but posts a net loss
Of every $100 in sales, $1.82 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +125.5% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $852. Peers typically go for $194.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +138.1%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 75.9%.
Tap to view numbers
It ranks #24 of 84 in the industry
Based on market cap of $2B.
PRGO#23 Perrigo Company plc $2B PER - AVDL#24 Avadel Pharmaceuticals plc $2B PER - 
PBH#24 Prestige Consumer Healthcare Inc $2B PER 12.4 
TRLV#25 Trulieve Cannabis Corp $2B PER - 
BCRX#26 Biocryst Pharmaceuticals Inc $2B PER - 
FAQ
What kind of company is AVDL?
AVDL belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AVDL?
The market cap of AVDL is approximately $2.1B, ranking 1,983 within its sector.
What is the 52-week high and low for AVDL?
AVDL has recorded a 52-week high of $23.57 and a low of $6.38.
